FDA has approved Merck’s Idvynso, introducing a differentiated, two-drug, non-INSTI, tenofovir-free HIV regimen that maintains viral suppression while offering a potentially more tolerable, simplified option for long-term patient management.
Merck secured FDA approval for Idvynso, a two-drug, single-tablet regimen combining doravirine and islatravir.
The approval marks a notable addition to the treatment landscape for adults living with HIV-1 who are virologically suppressed on a stable antiretroviral regimen.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The therapy introduces a non-INSTI, tenofovir-free option at a time when treatment strategies are increasingly focused on long-term tolerability, regimen simplification, and reducing cumulative drug exposure.
The approval positions Idvynso as a differentiated option within a competitive HIV market, particularly for patients seeking alternatives to integrase inhibitor-based or tenofovir-containing regimens.
As the population of people living with HIV ages, treatment decisions are increasingly shaped by comorbidities, drug-drug interactions, and the need to manage multiple chronic conditions alongside sustained viral suppression.
“Idvynso combines islatravir, a next-generation NRTI with multiple mechanisms of action, including translocation inhibition, with doravirine, an NNRTI with an established efficacy and safety profile,” said Dr. Eliav Barr, senior vice president and chief medical officer, Merck Research Laboratories. “As the only two-drug, non-INSTI, tenofovir-free regimen, Idvynso expands therapeutic diversity beyond the currently available oral treatment options.”
Clinical data supporting the approval of Idvynso comes from two Phase III, randomized, active-controlled trials evaluating virologically suppressed adults who either switched to Idvynso or remained on their baseline regimens.2 Across both studies, the regimen demonstrated non-inferior efficacy, with high rates of maintained viral suppression at 48 weeks.
In Trial 052, which evaluated patients switching from a bictegravir-based regimen, 1% of participants in both the Idvynso and comparator arms had HIV-1 RNA levels less than or equal to 50 copies/mL at Week 48, while 92% of patients receiving Idvynso maintained viral suppression.3 In Trial 051, 1% of patients who switched to Idvynso met the primary endpoint compared to 5% in the baseline antiretroviral therapy group, with 96% maintaining suppression at Week 48.2
Safety outcomes were generally comparable to existing regimens, with low rates of discontinuation due to adverse events. The most commonly reported side effects included diarrhea, dizziness, fatigue, abdominal distention, and headache, occurring at low frequencies across both studies.2,3
“Idvynso is the first non-INSTI, tenofovir-free, two-drug regimen to demonstrate non-inferior efficacy to standard oral antiretroviral regimens, including Biktarvy. This makes Idvynso a potential alternative for people with virologically suppressed HIV who may need to switch their treatment,” said Dr. Amy Colson, director of research at Community Resource Initiative in Boston.
The approval also reflects continued innovation within established HIV drug classes, rather than entirely new mechanisms, as manufacturers seek to differentiate therapies through improved safety profiles, dosing convenience, and patient-centric design.
Idvynso’s dual-mechanism approach, combining doravirine’s reverse transcriptase inhibition with islatravir’s multiple mechanisms, including translocation inhibition, underscores this strategy.1
With availability expected in U.S. pharmacies after May 11, Merck is positioning Idvynso as a flexible option for clinicians managing increasingly complex, long-term HIV care.
